[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338252-105":59,"doc-detail-338252-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","gpcrs-emerging-targets-for-novel-t-cell-immune-checkpoint-therapy","GPCRs - emerging targets for novel T cell immune checkpoint therapy","","Immune checkpoint blockade (ICB) is widely used for advanced solid tumors, yet durable restoration of the host anticancer immune response remains limited. G-protein coupled receptors (GPCRs), as cell-surface regulators of T lymphocyte activity, are emerging immunoregulatory targets. This review discusses notable GPCRs including GPR171, LPARs, GPR68, CB2, and prostaglandin E receptors, focusing on their expression, roles in immunity and cancer, therapeutic potential, and future research directions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/gpcrs-emerging-targets-for-novel-t-cell-immune-checkpoint-therapy/338252/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/gpcrs-emerging-targets-for-novel-t-cell-immune-checkpoint-therapy/338252.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is immune checkpoint blockade not universally successful in solid tumors?","Question",{"text":112,"@type":113},"Despite reinvigorating adaptive immunity, overall tumor response rates remain limited. Tumor immunogenicity and alternative immune escape pathways reduce durable benefit.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role do GPCRs play in regulating the immune system?",{"text":117,"@type":113},"GPCRs are ubiquitous cell-surface receptors important for immune responses, including mediating immune cell migration. They also provide mechanisms for T cell immune checkpoints and tumor immune evasion.",{"name":119,"@type":110,"acceptedAnswer":120},"Which GPCRs are highlighted as emerging immunoregulatory targets?",{"text":121,"@type":113},"The abstract highlights GPR171, lysophosphatidic acid receptors (LPARs), GPR68, cannabinoid receptor 2 (CB2), and prostaglandin E receptors, each discussed for potential antitumor effects through T cell and tumor microenvironment modulation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338252,1790799190,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Cancer Immunology, Immunotherapy (2024) 73:253 [https://doi.org/10.1007/s00262-024-03801-7](https://doi.org/10.1007/s00262-024-03801-7)  \nGPCRs: emerging targets for novel T cell immune checkpoint therapy  \nKaitlyn Dickinson1 · Elliott J. Yee1 · Isaac Vigil1 · Richard D. Schulick1 · Yuwen Zhu1  \nReceived: 24 May 2024 / Accepted: 5 August 2024 / Published online: 3 October 2024 © The Author(s) 2024  \nAbstract  \nAlthough immune checkpoint blockade (ICB) has become the mainstay of treatment for advanced solid organ malignancies, success in revitalizing the host anticancer immune response remains limited. G-protein coupled receptors (GPCRs) are abroad family of cell-surface proteins that have been regarded as main players in regulating the immune system, namely by mediating the activity ofT lymphocytes. Among the most novel immunoregulatory GPCRs include GPR171, lysophosphatidic acid receptors (LPARs), GPR68, cannabinoid receptor 2 (CB2), and prostaglandin E receptors, many of which have shown promise in mediating antitumor response via activation of cytotoxic T cells, inhibiting immunosuppressive lymphocytes, and facilitating immune cell infiltration within the tumor microenvironment across multiple types of cancers. This paper reviews our current understanding of some of the most novel GPCRs—their expression patterns, evolving roles within the immune system and cancer, potential therapeutic applications, and perspective for future investigation.  \nKeywords GPCRs · Immune checkpoint inhibitor · T cell · Tumor immunology  \nAbbreviations  \nΔ9THC 9-Tetrahydrocannabinol 2-AG 2-Arachidonoylglycerol A2AR Adenosine 2A receptor  \nAEA Anandamide  \nAPCs Antigen-presenting cells  \ncAMP Cyclic adenosine monophosphate COX Cyclooxygenase;  \nCRC Colorectal cancer  \nCTLA-4 Cytotoxic T-lymphocyte-associated protein-4 DC Dendritic cell  \nGPCRs G-coupled protein receptor ICB Immune checkpoint blockade  \nKO Knockout  \nLPAR Lysophosphatidic acid receptor lysoPS Lysophosphatidylserine  \nmAb Monoclonal antibody  \nMDSC Myeloid-derived suppressor cell NK Natural killer  \nPD-L1 Programmed death ligand 1  \nKaitlyn Dickinson and Elliott J. Yee have Shared first authorship.  \n* Yuwen Zhu [yuwen.zhu@cuanschutz.edu](yuwen.zhu@cuanschutz.edu)  \n1 Department of Surgery, Division of Surgical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA  \nPDAC Pancreatic cell adenocarcinoma SqCC Squamous cell cancer  \nTreg T regulatory cell  \nTAM Tumor-associated macrophage  \nTh T helper cell  \nTIGIT T cell immunoreceptor with immunoglobulin and ITIM domain  \nTILs Tumor infiltrating lymphocytes TME Tumor microenvironment  \nWT Wildtype  \nIntroduction  \nImmunotherapy in the form of immune checkpoint blockade (ICB) has revolutionized the treatment of various solid organ cancers; however, the widespread success of these therapies remains limited [1]. Currently, the most prominent ICB agents are monoclonal antibodies (mAbs) that block the coinhibitory interactions of the B7-CD28 superfamily such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death-(ligand) 1 (PD-1/-L1) on T cells with their ligands, CD80/86 and PD-L1, respectively, on antigen-presenting cells (APCs) and/or cancer cells [2] . These ICBs can reinvigorate the host adaptive immune system to target various tumors generating durable and specific antitumor effect. As such, they have become standard of care for  \nadvanced stage melanoma, renal cell carcinoma, esophageal, and non-small cell lung carcinoma following randomized trials demonstrating significant survival benefit with ICB therapy [3–5] . Despite marked improvement in outcomes for these select cancers, ICBs continue to be limited by tumor immunogenicity and the presence of alternative immune escape pathways, resulting in overall tumor response rates less than 30%[6] .  \nG-protein coupled receptors (GPCRs) comprise a ubiquitous family of cell-surface receptors that are known tobe important for immune response, with ","cbCailJXdCe0DjXa","https://ap.wps.com/l/cbCailJXdCe0DjXa","pdf",1138108,16,"English","# Introduction\n## Emerging GPCR members with T cell modulatory functions\n## Activated T cells and B7-CD28 regulation\n## Tumor immune evasion beyond B7-CD28 co-inhibition","[{\"question\":\"Why is immune checkpoint blockade not universally successful in solid tumors?\",\"answer\":\"Despite reinvigorating adaptive immunity, overall tumor response rates remain limited. Tumor immunogenicity and alternative immune escape pathways reduce durable benefit.\"},{\"question\":\"What role do GPCRs play in regulating the immune system?\",\"answer\":\"GPCRs are ubiquitous cell-surface receptors important for immune responses, including mediating immune cell migration. They also provide mechanisms for T cell immune checkpoints and tumor immune evasion.\"},{\"question\":\"Which GPCRs are highlighted as emerging immunoregulatory targets?\",\"answer\":\"The abstract highlights GPR171, lysophosphatidic acid receptors (LPARs), GPR68, cannabinoid receptor 2 (CB2), and prostaglandin E receptors, each discussed for potential antitumor effects through T cell and tumor microenvironment modulation.\"}]","GPCRs - emerging targets for novel T cell immune checkpoint therapy | PDF",1790022775,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ac54f9ed7de3034e4cb641c68eab298.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35c5052bf792ec150e2431eabcd4f973.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c248e851e53da6208fc43ed9f4d408a.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60b0eee3a688bd27f307abb3d5b8dc4e.webp",980,1301]